Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

45720

Sigma-Aldrich

Eserine salicylate salt

≥97.0% (N)

Synonym(s):

Physostigmine salicylate salt

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C15H21N3O2 · C7H6O3
CAS Number:
Molecular Weight:
413.47
Beilstein/REAXYS Number:
3900576
EC Number:
MDL number:
UNSPSC Code:
12352005
PubChem Substance ID:

biological source

synthetic

assay

≥97.0% (N)

form

powder

optical activity

[α]20/D −77±2°, c = 1% in ethanol

mp

181-183 °C

SMILES string

OC(=O)c1ccccc1O.CNC(=O)Oc2ccc3N(C)[C@H]4N(C)CC[C@@]4(C)c3c2

InChI

1S/C15H21N3O2.C7H6O3/c1-15-7-8-17(3)13(15)18(4)12-6-5-10(9-11(12)15)20-14(19)16-2;8-6-4-2-1-3-5(6)7(9)10/h5-6,9,13H,7-8H2,1-4H3,(H,16,19);1-4,8H,(H,9,10)/t13-,15+;/m1./s1

InChI key

HZOTZTANVBDFOF-PBCQUBLHSA-N

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Acetylcholinesterase inhibitor that crosses the blood-brain barrier and forms a carbamylated enzyme complex with acetyl cholinesterase that degrades slowly.

pictograms

Skull and crossbones

signalword

Danger

Hazard Classifications

Acute Tox. 2 Inhalation - Acute Tox. 2 Oral

Storage Class

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

S Rubnov et al.
Journal of pharmaceutical and biomedical analysis, 18(6), 939-945 (1999-01-30)
A simple stability-indicating HPLC assay has been developed for physostigmine salicylate, capable of following its degradation. A 250 x 5 mm i.d. column packed with 10 microm Bondapak C18 was used, with a mobile phase of acetonitrile - ammonium acetate
D K Lim et al.
Pharmacology, biochemistry, and behavior, 31(3), 627-631 (1988-11-01)
The present study demonstrates that continuous administration with physostigmine salicylate (0.12 or 0.24 mg/kg/hr via mini-osmotic pumps) induces toxicities (e.g., body weight loss, decreased water consumption, tremors, decreased body temperatures, mortality) in guinea pigs. Both blood and brain cholinesterase activity
F H Norris et al.
Clinical pharmacology and therapeutics, 54(6), 680-682 (1993-12-01)
We evaluated a double-blind, placebo-controlled, and double-crossover trial of oral physostigmine salicylate for a 9-month period in 13 of 25 patients with sporadic amyotrophic lateral sclerosis (ALS). A large dropout rate of 48% was secondary to eight deaths and four
M K Johnson et al.
Toxicology and applied pharmacology, 92(1), 34-41 (1988-01-01)
Organophosphorus-induced delayed polyneuropathy (OPIDP) is thought to result from organophosphorylation of neuropathy target esterase (NTE; formerly known as neurotoxic esterase), followed by an "aging" of the phosphorylated NTE. Protection against OPIDP should thus be achieved by production of an inhibited
D P Lunn et al.
Equine veterinary journal, 25(6), 483-487 (1993-11-01)
In an investigation of 2 closely related Miniature Horses with a history of excessive sleepiness, depression and episodes of collapse, a diagnosis of narcolepsy was made on the basis of neurological examination and pharmacological testing. Further investigations included electroencephalographic examination

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service